

# HCV Ab

**Third generation Enzyme Immunoassay  
for the determination of  
anti Hepatitis C Virus antibody  
in human serum and plasma**

- for "in vitro" diagnostic use only -



**DIA.PRO**

**Diagnostic Bioprobes Srl  
Via Columella n° 31  
20128 Milano - Italy**

Phone +39 02 27007161

Fax +39 02 26007726

e-mail: [diapro@tin.it](mailto:diapro@tin.it)

REF CVAB.CE  
96,192 ,480,960 Tests

## HCV Ab

### A. INTENDED USE

Third generation Enzyme ImmunoAssay (ELISA) for the determination of antibodies to Hepatitis C Virus in human plasma and sera. The kit may be used for the screening of blood units and the follow-up of HCV-infected patients.

For "in vitro" diagnostic use only.

### B. INTRODUCTION

The World Health Organization (WHO) define Hepatitis C infection as follows:

"Hepatitis C is a viral infection of the liver which had been referred to as parenterally transmitted "non A, non B hepatitis" until identification of the causative agent in 1989. The discovery and characterization of the hepatitis C virus (HCV) led to the understanding of its primary role in post-transfusion hepatitis and its tendency to induce persistent infection.

HCV is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and liver cancer. Globally, an estimated 170 million persons are chronically infected with HCV and 3 to 4 million persons are newly infected each year. HCV is spread primarily by direct contact with human blood. The major causes of HCV infection worldwide are use of unsterilized blood transfusions, and re-use of needles and syringes that have not been adequately sterilized. No vaccine is currently available to prevent hepatitis C and treatment for chronic hepatitis C is too costly for most persons in developing countries to afford. Thus, from a global perspective, the greatest impact on hepatitis C disease burden will likely be achieved by focusing efforts on reducing the risk of HCV transmission from nosocomial exposures (e.g. blood transfusions, unsafe injection practices) and high-risk behaviours (e.g. injection drug use).

Hepatitis C virus (HCV) is one of the viruses (A, B, C, D, and E), which together account for the vast majority of cases of viral hepatitis. It is an enveloped RNA virus in the *flaviviridae* family which appears to have a narrow host range. Humans and chimpanzees are the only known species susceptible to infection, with both species developing similar disease.

An important feature of the virus is the relative mutability of its genome, which in turn is probably related to the high propensity (80%) of inducing chronic infection. HCV is clustered into several distinct genotypes which may be important in determining the severity of the disease and the response to treatment.

The incubation period of HCV infection before the onset of clinical symptoms ranges from 15 to 150 days. In acute infections, the most common symptoms are fatigue and jaundice; however, the majority of cases (between 60% and 70%), even those that develop chronic infection, are asymptomatic. About 80% of newly infected patients progress to develop chronic infection. Cirrhosis develops in about 10% to 20% of persons with chronic infection, and liver cancer develops in 1% to 5% of persons with chronic infection over a period of 20 to 30 years. Most patients suffering from liver cancer who do not have hepatitis B virus infection have evidence of HCV infection. The mechanisms by which HCV infection leads to liver cancer are still unclear. Hepatitis C also exacerbates the severity of underlying liver disease when it coexists with other hepatic conditions. In particular, liver disease progresses more rapidly among persons with

alcoholic liver disease and HCV infection. HCV is spread primarily by direct contact with human blood. Transmission through blood transfusions that are not screened for HCV infection, through the reuse of inadequately sterilized needles, syringes or other medical equipment, or through needle-sharing among drug-users, is well documented. Sexual and perinatal transmission may also occur, although less frequently. Other modes of transmission such as social, cultural, and behavioural practices using percutaneous procedures (e.g. ear and body piercing, circumcision, tattooing) can occur if inadequately sterilized equipment is used. HCV is not spread by sneezing, hugging, coughing, food or water, sharing eating utensils, or casual contact.

In both developed and developing countries, high risk groups include injecting drug users, recipients of unsterilized blood, haemophiliacs, dialysis patients and persons with multiple sex partners who engage in unprotected sex. In developed countries, it is estimated that 90% of persons with chronic HCV infection are current and former injecting drug users and those with a history of transfusion of unsterilized blood or blood products. In many developing countries, where unsterilized blood and blood products are still being used, the major means of transmission are unsterilized injection equipment and unsterilized blood transfusions. In addition, people who use traditional scarification and circumcision practices are at risk if they use or re-use unsterilized tools.

WHO estimates that about 170 million people, 3% of the world's population, are infected with HCV and are at risk of developing liver cirrhosis and/or liver cancer. The prevalence of HCV infection in some countries in Africa, the Eastern Mediterranean, South-East Asia and the Western Pacific (when prevalence data are available) is high compared to some countries in North America and Europe.

Diagnostic tests for HCV are used to prevent infection through screening of donor blood and plasma, to establish the clinical diagnosis and to make better decisions regarding medical management of a patient. Diagnostic tests commercially available today are based on Enzyme immunoassays (EIA) for the detection of HCV specific antibodies. EIAs can detect more than 95% of chronically infected patients but can detect only 50% to 70% of acute infections. A recombinant immunoblot assay (RIBA) that identifies antibodies which react with individual HCV antigens is often used as a supplemental test for confirmation of a positive EIA result. Testing for HCV circulating by amplification tests RNA (e.g. polymerase chain reaction or PCR, branched DNA assay) is also being utilized for confirmation of serological results as well as for assessing the effectiveness of antiviral therapy. A positive result indicates the presence of active infection and a potential for spread of the infection and or/the development of chronic liver disease.

Antiviral drugs such as interferon taken alone or in combination with ribavirin, can be used for the treatment of persons with chronic hepatitis C, but the cost of treatment is very high. Treatment with interferon alone is effective in about 10% to 20% of patients. Interferon combined with ribavirin is effective in about 30% to 50% of patients. Ribavirin does not appear to be effective when used alone.

There is no vaccine against HCV. Research is in progress but the high mutability of the HCV genome complicates vaccine development. Lack of knowledge of any protective immune response following HCV infection also impedes vaccine research. It is not known whether the immune system is able to eliminate the virus.

Some studies, however, have shown the presence of virus neutralizing antibodies in patients with HCV infection. In the absence of a vaccine, all precautions to prevent infection must be taken including (a) screening and testing of blood and organ donors; (b) Virus inactivation of plasma derived products; (c) implementation and maintenance of infection control practices in health care settings, including appropriate sterilization of medical and dental equipment; (d) promotion of behaviour change among the general public and health care workers to reduce overuse of injections and to use safe injection practices; and (e) Risk reduction counselling for persons with high-risk drug and sexual practices. “

The genome encodes for structural components, a nucleocapsid protein and two envelope glycoproteins, and functional constituents involved in the virus replication and protein processing. The nucleocapsid-encoding region seems to be the most conservative among the isolates obtained all over the world.

### C. PRINCIPLE OF THE TEST

Microplates are coated with HCV-specific antigens derived from “core” and “ns” regions encoding for conservative and immunodominant antigenic determinants (Core peptide, recombinant NS3, NS4 and NS5 peptides). The solid phase is first treated with the diluted sample and HCV Ab are captured, if present, by the antigens. After washing out all the other components of the sample, in the 2<sup>nd</sup> incubation bound HCV antibodies, IgG and IgM as well, are detected by the addition of polyclonal specific anti hlgG&M antibodies, labelled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti HCV antibodies present in the sample. A cut-off value let optical densities be interpreted into HCV antibody negative and positive results.

### D. COMPONENTS

Code CVAB.CE contains reagents for 192 tests.

#### 1. Microplate **MICROPLATE**

n°2 microplates  
12 strips of 8 microwells coated with Core peptide, recombinant NS3, NS4 and NS5 peptides. Plates are sealed into a bag with desiccant.

#### 2. Negative Control **CONTROL -**

1x4.0ml/vial. Ready to use control. It contains 1% goat serum proteins, 10 mM Na-citrate buffer pH 6.0 +/-0.1, 0.5% Tween 20, 0.09% Na-azide and 0.1% Kathon GC as preservatives. The negative control is olive green colour coded.

#### 3. Positive Control **CONTROL +**

1x4.0ml/vial. Ready to use control. It contains 1% goat serum proteins, human antibodies positive to HCV, 10 mM Na-citrate buffer pH 6.0 +/-0.1, 0.5% Tween 20, 0.09% Na-azide and 0.1% Kathon GC as preservatives. The Positive Control is dark green colour coded.

#### 4. Calibrator **CAL ...**

n°2 vials. Lyophilized calibrator. To be dissolved with the volume of EIA grade water reported on the label. It contains foetal bovine serum proteins, human antibodies to HCV whose content is calibrated on the NIBSC Working Standard code 99/588-003-WI, 10 mM Na-citrate buffer pH 6.0 +/-0.1, 0.3

mg/ml gentamicine sulphate and 0.1% Kathon GC as preservatives.

**Note: The volume necessary to dissolve the content of the vial may vary from lot to lot. Please use the right volume reported on the label .**

#### 5. Wash buffer concentrate **WASHBUF 20X**

2x60ml/bottle. 20x concentrated solution. Once diluted, the wash solution contains 10 mM phosphate buffer pH 7.0+/-0.2, 0.05% Tween 20 and 0.05% Kathon GC.

#### 6. Enzyme Conjugate **CONJ**

2x16ml/vial. Ready to use and red colour coded reagent. It contains Horseradish Peroxidase conjugated goat polyclonal antibodies to human IgG and IgM, 5% BSA, 10 mM Tris buffer pH 6.8+/-0.1, 0.1% Kathon GC and 0.02% gentamicine sulphate as preservatives.

#### 7. Chromogen/Substrate **SUBS TMB**

2x16ml/vial. Ready-to-use component. It contains 50 mM citrate-phosphate buffer pH 3.5-3.8, 4% dimethylsulphoxide, 0.03% tetra-methyl-benzidine or TMB and 0.02% hydrogen peroxide or H2O2.

**Note: To be stored protected from light as sensitive to strong illumination.**

#### 8. Assay Diluent **DILAS**

1x15ml/vial. 10 mM tris buffered solution pH 8.0 +/-0.1 containing 0.1% Kathon GC for the pre-treatment of samples and controls in the plate, blocking interference.

#### 9. Sulphuric Acid **H2SO4 0.3 M**

1x32ml/vial. It contains 0.3 M H2SO4 solution. Attention: Irritant (Xi R36/38; S2/26/30).

#### 10. Sample Diluent: **DILSPE**

2x50ml/vial. It contains 1% goat serum proteins, 10 mM Na-citrate buffer pH 6.0 +/-0.1, 0.5% Tween 20, 0.09% Na-azide and 0.1% Kathon GC as preservatives. To be used to dilute the sample.

**Note: The diluent changes colour from olive green to dark bluish green in the presence of sample.**

11. Plate sealing foils n°4

12. Package insert n°1

**Important note:** Only upon specific request , Dia.Pro can supply reagents for 96, 480, 960 tests , as reported below:

1. Microplate	n°1	n°5	n°10
2. Negative Control	1x2.0ml/vial	1x10ml/vial	1x20.ml/vial
3. Positive Control	1x2.0ml/vial	1x10ml/vial	1x20.ml/vial
4. Calibrator	n°1 vial	n°5 vials	n°10 vials
5. Wash buff conc	1x60ml/bottle	2x150ml/bottles	4x150ml/bottles
6. Enz. Conjugate	1x16ml/vial	2x40ml/bottles	4x40ml/bottles
7. Chromog/Subs	1x16ml/vial	2x40ml/bottles	4x40ml/bottles
8. Assay Diluent	1x8ml/vial	1x40ml/bottle	1x80ml/bottle
9. Sulphuric Acid	1x15ml/vial	1x80ml/bottle	2x80ml/bottles
10. Sample Diluent	1x50ml/vial	2x125ml/bottles	4x125ml/bottles
11. Plate seal foils	n°2	n°10	n°20
12. Pack. insert	n°1	n°1	n°1
<b>Number of tests</b>	<b>96</b>	<b>480</b>	<b>960</b>
<b>Code</b>	<b>CVAB.CE.96</b>	<b>CVAB.CE.480</b>	<b>CVAB.CE.960</b>

#### E. MATERIALS REQUIRED BUT NOT PROVIDED

1. Calibrated Micropipettes (200ul and 10ul) and disposable plastic tips.
2. EIA grade water (bidistilled or deionised, charcoal treated to remove oxidizing chemicals used as disinfectants).
3. Timer with 60 minute range or higher.
4. Absorbent paper tissues.
5. Calibrated ELISA microplate thermostatic incubator capable to provide a temperature of +37°C.
6. Calibrated ELISA microwell reader with 450nm (reading) and possibly with 620-630nm (blanking) filters.
7. Calibrated ELISA microplate washer.
8. Vortex or similar mixing tools.

#### F. WARNINGS AND PRECAUTIONS

1. The kit has to be used by skilled and properly trained technical personnel only, under the supervision of a medical doctor responsible of the laboratory.
2. When the kit is used for the screening of blood units and blood components, it has to be used in a laboratory certified and qualified by the national authority in that field (Ministry of Health or similar entity) to carry out this type of analysis.
3. All the personnel involved in performing the assay have to wear protective laboratory clothes, talc-free gloves and glasses. The use of any sharp (needles) or cutting (blades) devices should be avoided. All the personnel involved should be trained in biosafety procedures, as recommended by the Center for Disease Control, Atlanta, U.S. and reported in the National Institute of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.
4. All the personnel involved in sample handling should be vaccinated for HBV and HAV, for which vaccines are available, safe and effective.
5. The laboratory environment should be controlled so as to avoid contaminants such as dust or air-borne microbial agents, when opening kit vials and microplates and when performing the test. Protect the Chromogen/Substrate from strong light and avoid vibration of the bench surface where the test is undertaken.
6. Upon receipt, store the kit at 2.8°C into a temperature controlled refrigerator or cold room.
7. Do not interchange components between different lots of the kits. It is recommended that components between two kits of the same lot should not be interchanged.
8. Check that the reagents are clear and do not contain visible heavy particles or aggregates. If not, advise the laboratory supervisor to initiate the necessary procedures for kit replacement.
9. Avoid cross-contamination between serum/plasma samples by using disposable tips and changing them after each sample.
10. Avoid cross-contamination between kit reagents by using disposable tips and changing them between the use of each one.
11. Do not use the kit after the expiration date stated on the external container and internal (vials) labels.
12. Treat all specimens as potentially infective. All human serum specimens should be handled at Biosafety Level 2, as recommended by the Center for Disease Control, Atlanta, U.S. in compliance with what reported in the Institutes of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.
13. The use of disposable plastic-ware is recommended in the preparation of the liquid components or in transferring components into automated workstations, in order to avoid cross contamination.
14. Waste produced during the use of the kit has to be discarded in compliance with national directives and laws concerning laboratory waste of chemical and biological substances. In particular, liquid waste generated from the washing procedure, from residuals of controls and from samples has to be treated as potentially infective material and inactivated

before waste. Suggested procedures of inactivation are treatment with a 10% final concentration of household bleach for 16-18 hrs or heat inactivation by autoclave at 121°C for 20 min..

15. Accidental spills from samples and operations have to be adsorbed with paper tissues soaked with household bleach and then with water. Tissues should then be discarded in proper containers designated for laboratory/hospital waste.
16. The Sulphuric Acid is an irritant. In case of spills, wash the surface with plenty of water
17. Other waste materials generated from the use of the kit (example: tips used for samples and controls, used microplates) should be handled as potentially infective and disposed according to national directives and laws concerning laboratory wastes.

#### G. SPECIMEN: PREPARATION AND RECOMMANDATIONS

1. Blood is drawn aseptically by venepuncture and plasma or serum is prepared using standard techniques of preparation of samples for clinical laboratory analysis. No influence has been observed in the preparation of the sample with citrate, EDTA and heparin.
2. Avoid any addition of preservatives to samples; especially sodium azide as this chemical would affect the enzymatic activity of the conjugate, generating false negative results.
3. Samples have to be clearly identified with codes or names in order to avoid misinterpretation of results. When the kit is used for the screening of blood units, bar code labeling and electronic reading is strongly recommended.
4. Haemolysed (red) and visibly hyperlipemic ("milky") samples have to be discarded as they could generate false results. Samples containing residues of fibrin or heavy particles or microbial filaments and bodies should be discarded as they could give rise to false results.
5. Sera and plasma can be stored at +2°.8°C for up to five days after collection. For longer storage periods, samples can be stored frozen at -20°C for several months. Any frozen samples should not be frozen/thawed more than once as this may generate particles that could affect the test result.
6. If particles are present, centrifuge at 2.000 rpm for 20 min or filter using 0.2-0.8u filters to clean up the sample for testing.

#### H. PREPARATION OF COMPONENTS AND WARNINGS

A study conducted on an opened kit has not pointed out any relevant loss of activity up to 6 re-use of the device and up to 6 months.

##### 1. Microplates:

Allow the microplate to reach room temperature (about 1 hr) before opening the container. Check that the desiccant is not turned to dark green, indicating a defect of manufacturing. In this case call Dia.Pro's customer service. Unused strips have to be placed back into the aluminium pouch, in presence of desiccant supplied, firmly zipped and stored at +2°.8°C. When opened the first time, residual strips are stable till the indicator of humidity inside the desiccant bag turns from yellow to green.

##### 2. Negative Control:

Ready to use. Mix well on vortex before use.

##### 3. Positive Control:

Ready to use. Mix well on vortex before use. Handle this component as potentially infective, even if HCV, eventually present in the control, has been chemically inactivated.

##### 4. Calibrator:

Dissolve carefully the content of the lyophilised vial with the volume of EIA grade water reported on its label. Mix well on vortex before use.

Handle this component as potentially infective, even if HCV, eventually present in the control, has been chemically inactivated.

**Note:** When dissolved the Calibrator is not stable. Store in aliquots at  $-20^{\circ}\text{C}$ .

#### 5. Wash buffer concentrate:

The 20x concentrated solution has to be diluted with EIA grade water up to 1200 ml and mixed gently end-over-end before use. As some salt crystals may be present into the vial, take care to dissolve all the content when preparing the solution.

In the preparation avoid foaming as the presence of bubbles could give origin to a bad washing efficiency.

**Note:** Once diluted, the wash solution is stable for 1 week at  $+2..8^{\circ}\text{C}$ .

#### 6. Enzyme conjugate:

Ready to use. Mix well on vortex before use.

Be careful not to contaminate the liquid with oxidizing chemicals, air-driven dust or microbes.

If this component has to be transferred use only plastic, possibly sterile disposable containers.

#### 7. Chromogen/Substrate:

Ready to use. Mix well on vortex before use.

Be careful not to contaminate the liquid with oxidizing chemicals, air-driven dust or microbes.

Do not expose to strong illumination, oxidizing agents and metallic surfaces.

If this component has to be transferred use only plastic, possible sterile disposable container.

#### 8. Assay Diluent:

Ready to use. Mix well on vortex before use.

#### 9. Sulphuric Acid:

Ready to use. Mix well on vortex before use.

Attention: Irritant (Xi R36/38; S2/26/30)

Legenda: R 36/38 = Irritating to eyes and skin.

S 2/26/30 = In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

#### 10. Sample Diluent:

Ready to use. Mix well on vortex before use.

and positive reference samples, and check to match the values reported below in the sections "Validation of Test" and "Assay Performances". Regular calibration of the volumes delivered by, and maintenance (decontamination and cleaning of needles) of the washer has to be carried out according to the instructions of the manufacturer.

4. Incubation times have a tolerance of  $\pm 5\%$ .
5. The ELISA microplate reader has to be equipped with a reading filter of 450nm and ideally with a second filter (620-630nm) for blanking purposes. Its standard performances should be (a) bandwidth  $\leq 10$  nm; (b) absorbance range from 0 to  $\geq 2.0$ ; (c) linearity to  $\geq 2.0$ ; repeatability  $\geq 1\%$ . Blanking is carried out on the well identified in the section "Assay Procedure". The optical system of the reader has to be calibrated regularly to ensure that the correct optical density is measured. It should be regularly maintained according to the manufacturer's instructions.
6. When using an ELISA automated work station, all critical steps (dispensation, incubation, washing, reading, data handling) have to be carefully set, calibrated, controlled and regularly serviced in order to match the values reported in the section O "Internal Quality Control". The assay protocol has to be installed in the operating system of the unit and validated as for the washer and the reader. In addition, the liquid handling part of the station (dispensation and washing) has to be validated and correctly set. Particular attention must be paid to avoid carry over by the needles used for dispensing and for washing. This must be studied and controlled to minimize the possibility of contamination of adjacent wells. The use of ELISA automated work stations is recommended for blood screening when the number of samples to be tested exceed 20-30 units per run.
7. When using automatic devices, in case the vial holder of the instrument does not fit with the vials supplied in the kit, transfer the solution into appropriate containers and label them with the same label peeled out from the original vial. This operation is important in order to avoid mismatching contents of vials, when transferring them. When the test is over, return the secondary labeled containers to  $2..8^{\circ}\text{C}$ , firmly capped.
8. Dia.Pro's customer service offers support to the user in the setting and checking of instruments used in combination with the kit, in order to assure compliance with the requirements described. Support is also provided for the installation of new instruments to be used with the kit.

### I. INSTRUMENTS AND TOOLS USED IN COMBINATION WITH THE KIT

1. Micropipettes have to be calibrated to deliver the correct volume required by the assay and must be submitted to regular decontamination (household alcohol, 10% solution of bleach, hospital grade disinfectants) of those parts that could accidentally come in contact with the sample. They should also be regularly maintained in order to show a precision of 1% and a trueness of  $\pm 2\%$ . Decontamination of spills or residues of kit components should also be carried out regularly.
2. The ELISA incubator has to be set at  $+37^{\circ}\text{C}$  (tolerance of  $\pm 0.5^{\circ}\text{C}$ ) and regularly checked to ensure the correct temperature is maintained. Both dry incubators and water baths are suitable for the incubations, provided that the instrument is validated for the incubation of ELISA tests.
3. The ELISA washer is extremely important to the overall performances of the assay. The washer must be carefully validated and correctly optimized using the kit controls and reference panels, before using the kit for routine laboratory tests. Usually 4-5 washing cycles (aspiration + dispensation of 350ul/well of washing solution = 1 cycle) are sufficient to ensure that the assay performs as expected. A soaking time of 20-30 seconds between cycles is suggested. In order to set correctly their number, it is recommended to run an assay with the kit controls and well characterized negative

### L. PRE ASSAY CONTROLS AND OPERATIONS

1. Check the expiration date of the kit printed on the external label of the kit box. Do not use if expired.
2. Check that the liquid components are not contaminated by naked-eye visible particles or aggregates. Check that the Chromogen/Substrate is colorless or pale blue by aspirating a small volume of it with a sterile transparent plastic pipette. Check that no breakage occurred in transportation and no spillage of liquid is present inside the box. Check that the aluminum pouch, containing the microplate, is not punctured or damaged.
3. Dilute all the content of the 20x concentrated Wash Solution as described above.
4. Dissolve the Calibrator as described above.
5. Allow all the other components to reach room temperature (about 1 hr) and then mix as described.
6. Set the ELISA incubator at  $+37^{\circ}\text{C}$  and prepare the ELISA washer by priming with the diluted washing solution, according to the manufacturers instructions. Set the right number of washing cycles as found in the validation of the instrument for its use with the kit.
7. Check that the ELISA reader has been turned on at least 20 minutes before reading.
8. If using an automated workstation, turn it on, check settings and be sure to use the right assay protocol.

- Check that the micropipettes are set to the required volume.
- Check that all the other equipment is available and ready to use.
- In case of problems, do not proceed further with the test and advise the supervisor.

#### M. ASSAY PROCEDURE

The assay has to be carried out according to what reported below, taking care to maintain the same incubation time for all the samples in testing.

##### Automated assay:

In case the test is carried out automatically with an ELISA system, we suggest to make the instrument aspirate 200 ul Sample Diluent and then 10 ul sample.

All the mixture is then carefully dispensed directly into the appropriate sample well of the microplate. Before the next sample is aspirated, needles have to be duly washed to avoid any cross-contamination among samples.

Do not dilute controls/calibrator as they are ready to use.

Dispense 200 ul controls/calibrator in the appropriate control/calibration wells.

**Important Note:** Visually monitor that samples have been diluted and dispensed into appropriate wells. This is simply achieved by checking that the colour of dispensed samples has turned to dark bluish-green while the colour of the negative control has remained olive green.

For the next operations follow the operative instructions reported below for the Manual Assay.

It is strongly recommended to check that the time lap between the dispensation of the first and the last sample will be calculated by the instrument and taken into consideration by delaying the first washing operation accordingly.

##### Manual assay:

- Place the required number of Microwells in the microwell holder. Leave the 1<sup>st</sup> well empty for the operation of blanking.
- Dispense 200 ul of Negative Control in triplicate, 200 ul Calibrator in duplicate and 200 ul Positive Control in single in proper wells. Do not dilute Controls and Calibrator as they are pre-diluted, ready to use !
- Add 200 ul of Sample Diluent (DILSPE) to all the sample wells; then dispense 10 ul sample in each properly identified well. Mix gently the plate, avoiding overflowing and contaminating adjacent wells, in order to fully disperse the sample into its diluent.

**Important note:** Check that the colour of the Sample Diluent, upon addition of the sample, changes from light green to dark bluish green, monitoring that the sample has been really added.

- Dispense 50 ul Assay Diluent (DILAS) into all the controls/calibrator and sample wells. Check that the color of samples has turned to dark blue.
- Incubate the microplate for **45 min at +37°C**.

**Important note:** Strips have to be sealed with the adhesive sealing foil, supplied, only when the test is carried out manually. Do not cover strips when using ELISA automatic instruments.

- Wash the microplate with an automatic washer by delivering and aspirating 350ul/well of diluted washing solution as reported previously (section I.3).
- Pipette 100µl Enzyme Conjugate into each well, except the 1<sup>st</sup> blanking well, and cover with the sealer. Check that this red coloured component has been dispensed in all the wells, except A1.

**Important note:** Be careful not to touch the plastic inner surface of the well with the tip filled with the Enzyme Conjugate. Contamination might occur.

- Incubate the microplate for **45 min at +37°C**.
- Wash microwells as in step 6.
- Pipette 100µl Chromogen/Substrate mixture into each well, the blank well included. Then incubate the microplate at **room temperature (18-24°C) for 15 minutes**.

**Important note:** Do not expose to strong direct illumination. High background might be generated.

- Pipette 100µl Sulphuric Acid into all the wells using the same pipetting sequence as in step 10 to stop the enzymatic reaction. Addition of acid will turn the positive control and positive samples from blue to yellow.
- Measure the colour intensity of the solution in each well, as described in section I.5, at 450nm filter (reading) and possibly at 620-630nm (background subtraction), blanking the instrument on A1.

##### Important notes:

- If the second filter is not available ensure that no finger prints are present on the bottom of the microwell before reading at 450nm. Finger prints could generate false positive results on reading.
- Reading has to be carried out just after the addition of the Stop Solution and anyway not any longer than 20 minutes after its addition. Some self oxidation of the chromogen can occur leading to high background.
- Shaking at 350 ±150 rpm during incubation has been proved to increase the sensitivity of the assay of about 20%.

#### N. ASSAY SCHEME

Method	Operations
Controls & Calibrator	200 ul
Samples	200ul dil.+10ul
Assay Diluent (DILAS)	50 ul
<b>1<sup>st</sup> incubation</b>	<b>45 min</b>
Temperature	+37°C
Wash step	4-5 cycles
Enzyme conjugate	100 ul
<b>2<sup>nd</sup> incubation</b>	<b>45 min</b>
Temperature	+37°C
Wash step	4-5 cycles
TMB/H <sub>2</sub> O <sub>2</sub>	100 ul
<b>3<sup>rd</sup> incubation</b>	<b>15 min</b>
Temperature	r.t.
Sulphuric Acid	100 ul
Reading OD	450nm

An example of dispensation scheme is reported below:

		Microplate											
		1	2	3	4	5	6	7	8	9	10	11	12
A	BLK	S2											
B	NC	S3											
C	NC	S4											
D	NC	S5											
E	CAL	S6											
F	CAL	S7											
G	PC	S8											
H	S1	S9											

Legenda: BLK = Blank NC = Negative Control  
CAL = Calibrator PC = Positive Control S = Sample

### O. INTERNAL QUALITY CONTROL

A check is carried out on the controls and the calibrator any time the kit is used in order to verify whether their OD450nm values are as expected and reported in the table below.

Check	Requirements
Blank well	< 0.100 OD450nm value
Negative Control (NC)	< 0.050 mean OD450nm value after blanking
Calibrator	S/Co > 1.1
Positive Control	> 1.000 OD450nm value

If the results of the test match the requirements stated above, proceed to the next section.

If they do not, do not proceed any further and operate as follows:

Problem	Check
Blank well > 0.100 OD450nm	1. that the Chromogen/Sustrate solution has not got contaminated during the assay
Negative Control (NC) > 0.050 OD450nm after blanking	1. that the washing procedure and the washer settings are as validated in the pre qualification study; 2. that the proper washing solution has been used and the washer has been primed with it before use; 3. that no mistake has been done in the assay procedure (dispensation of positive control instead of negative control); 4. that no contamination of the negative control or of their wells has occurred due to positive samples, to spills or to the enzyme conjugate; 5. that micropipettes haven't got contaminated with positive samples or with the enzyme conjugate 6. that the washer needles are not blocked or partially obstructed.
Calibrator S/Co < 1.1	1. that the procedure has been correctly executed; 2. that no mistake has been done in its distribution (ex.: dispensation of negative control instead of control serum) 3. that the washing procedure and the washer settings are as validated in the pre qualification study; 4. that no external contamination of the calibrator has occurred.
Positive Control < 1.000 OD450nm	1. that the procedure has been correctly executed; 2. that no mistake has been done in the distribution of controls (dispensation of negative control instead of positive control. In this case, the negative control will have an OD450nm value > 0.150, too. 3. that the washing procedure and the washer settings are as validated in the pre qualification study; 4. that no external contamination of the positive control has occurred.

Should these problems happen, after checking, report any residual problem to the supervisor for further actions.

### P. CALCULATION OF THE CUT-OFF

The tests results are calculated by means of a cut-off value determined with the following formula on the mean OD450nm value of the Negative Control (NC):

$$NC + 0.350 = \text{Cut-Off (Co)}$$

The value found for the test is used for the interpretation of results as described in the next paragraph.

**Important note:** When the calculation of results is done by the operative system of an ELISA automated work station be sure that the proper formulation is used to calculate the cut-off value and generate the right interpretations of results.

### Q. INTERPRETATION OF RESULTS

Test results are interpreted as ratio of the sample OD450nm and the Cut-Off value (or S/Co) according to the following table:

S/Co	Interpretation
< 0.9	Negative
0.9 - 1.1	Equivocal
> 1.1	Positive

A negative result indicates that the patient has not been infected by HCV or that the blood unit may be transfused.

Any patient showing an equivocal result should be tested again on a second sample taken 1-2 weeks later from the patient and examined. The blood unit should not be transfused.

A positive result is indicative of HCV infection and therefore the patient should be treated accordingly or the blood unit should be discarded.

#### Important notes:

1. Interpretation of results should be done under the supervision of the responsible of the laboratory to reduce the risk of judgment errors and misinterpretations.
2. Any positive result should be confirmed by an alternative method capable to detect IgG and IgM antibodies (confirmation test) before a diagnosis of viral hepatitis is formulated.
3. As proved in the Performance Evaluation of the product, the assay is able to detect seroconversion to anti HCV core antibodies **earlier** than some other commercial kits. Therefore a positive result, not confirmed with these commercial kits, does not have to be ruled out as a false positive result ! The sample has to be anyway submitted to a confirmation test (supplied upon request by DiaPro srl, code CCONF).
4. As long as the assay is able to detect also IgM antibodies some discrepant results with other commercial products for the detection of anti HCV antibodies - lacking anti hlgM conjugate in the formulation of the enzyme tracer and therefore missing IgM reactivity - may be present. The real positivity of the sample for antibodies to HCV should be then confirmed by examining also IgM reactivity, important for the diagnosis of HCV infection.
5. When test results are transmitted from the laboratory to an informatics centre, attention has to be done to avoid erroneous data transfer.
6. Diagnosis of viral hepatitis infection has to be done and released to the patient only by a qualified medical doctor.

An example of calculation is reported below:

The following data must not be used instead of real figures obtained by the user.

Negative Control: 0.019 – 0.020 – 0.021 OD450nm  
Mean Value: 0.020 OD450nm  
Lower than 0.050 – Accepted

Positive Control: 2.189 OD450nm  
Higher than 1.000 – Accepted  
Cut-Off = 0.020 + 0.350 = 0.370

Calibrator: 0.550 - 0.530 OD450nm  
 Mean value: 0.540 OD450nm S/Co = 1.4  
 S/Co higher than 1.1 – Accepted

Sample 1: 0.070 OD450nm  
 Sample 2: 1.690 OD450nm  
 Sample 1 S/Co < 0.9 = negative  
 Sample 2 S/Co > 1.1 = positive

## R. PERFORMANCES

Evaluation of Performances has been conducted in accordance to what reported in the Common Technical Specifications or CTS (art. 5, Chapter 3 of IVD Directive 98/79/EC).

### 1. LIMIT OF DETECTION

The limit of detection of the assay has been calculated by means of the British Working Standard for anti-HCV, NIBSC code 99/588-003-WI. The table below reports the mean OD450nm values of this standard when diluted in negative plasma and then examined.

Dilution	Lot # 1	Lot # 2
Factor	S/Co	S/Co
1 X	2.0	2.0
2 X	1.1	1.2
4 X	0.7	0.8
8 X	0.5	0.5
Negative plasma	0.3	0.3

In addition the sample coded Accurun 1 – series 3000 - supplied by Boston Biomedica Inc., USA, has been evaluated “in toto” showing the results below:

CVAB.CE Lot ID	Accurun 1 Series	S/Co
1201	3000	1.5
0602	3000	1.5
1202	3000	1.9

In addition, n°7 samples, tested positive for HCV Ab with Ortho HCV 3.0 SAVE, code 930820, lot. # EXE065-1, were diluted in HCV Ab negative plasma in order to generate limiting dilutions and then tested again on CVAB.CE, lot. # 1202, and Ortho. The following table reports the data obtained.

Sample n°	Limit Dilution	CVAB.CE S/Co	Ortho 3.0 S/Co
1	256 X	1.9	1.3
2	256 X	1.9	0.7
3	256 X	2.4	1.0
4	128 X	2.5	3.2
5	85 X	3.3	1.4
6	128 X	2.2	0.8
7	135 X	3.2	2.2

### 2. DIAGNOSTIC SPECIFICITY AND SENSITIVITY

The Performance Evaluation of the device was carried out in a trial conducted on more than total 5000 samples.

#### 2.1 Diagnostic specificity:

It is defined as the probability of the assay of scoring negative in the absence of specific analyte. A total of more 5000 unselected donors, including 1<sup>st</sup> time donors, were examined.

The diagnostic specificity was assessed against a kit US FDA approved.

5043 blood donors were tested providing a specificity of 99.5%. 210 hospitalized patients were tested for HCV Ab; a diagnostic specificity of 99.5% was found.

Moreover, diagnostic specificity was assessed by testing 162 potentially interfering specimens (other infectious diseases, E.coli antibody positive, patients affected by non viral hepatic diseases, dialysis patients, pregnant women, hemolized, lipemic, etc.). A value of specificity of 100% was assessed.

No false reactivity due to the method of specimen preparation has been observed. Both plasma, derived with different standard techniques of preparation (citrate, EDTA and heparin), and sera have been used to determine the value of specificity.

Frozen specimens have been tested, as well, to check for interferences due to collection and storage.

No interference was observed.

#### 2.2 Diagnostic Sensitivity

It defined as the probability of the assay of scoring positive in the presence of specific analyte.

The diagnostic sensitivity has been assessed externally on a total number of 359 specimens; a diagnostic sensitivity of 100% was found. Internally more than other 50 positive samples were tested, providing a value of diagnostic sensitivity of again 100%. Positive samples from infections carried out by different genotypes of HCV were tested as well.

Furthermore, most of seroconversion panels available from Boston Biomedica Inc., have been studied.

Results are reported below for some of them.

#### BBI WWHV 301

Sample ID	CVAB.CE results S/Co	Ortho HCV 3 S/Co	Sample ID	CVAB.CE results S/Co	Ortho HCV 3 S/Co
01	11.3	> 5.0	11	3.2	> 5.0
02	11.3	> 5.0	12	11.3	> 5.0
03	11.3	> 5.0	13	11.3	> 5.0
04	10.7	> 5.0	14	11.2	> 5.0
05	0.1	0.0	15	8.0	> 5.0
06	11.2	> 5.0	16	6.3	> 5.0
07	4.2	> 5.0	17	9.0	> 5.0
08	0.2	0.1	18	10.6	> 5.0
09	8.5	> 5.0	19	1.6	> 5.0
10	11.3	> 5.0	20	10.7	> 5.0

#### BBI PHV 920

Sample ID	CVAB.CE S/Co	Ortho SAVE S/Co
01	0.1	0.0
02	0.1	0.0
03	0.2	0.0
04	0.7	0.4
05	2.0	2.1
06	4.4	2.9
07	4.7	> 4.8
08	4.9	> 4.8
09	5.7	> 4.8
10	6.2	> 4.8

**BBI PHV 908**

Sample ID	CVAB.CE S/Co	Ortho 3.0 S/Co
01	0.2	0.0
02	0.2	0.0
03	0.2	0.0
04	0.4	0.5
05	0.5	0.7
06	1.4	1.6
07	3.7	3.2
08	5.2	3.7
09	6.0	4.5
10	7.2	4.8
11	7.9	4.9
12	8.1	5.1
13	8.2	5.1

**BBI PHV 905**

Sample ID	CVAB.CE S/Co	Ortho 3.0 S/Co
01	0.2	0.0
02	0.2	0.0
03	0.2	0.0
04	0.4	0.5
05	0.5	0.7
06	1.4	1.6
07	3.7	3.2
08	5.2	3.7
09	6.0	4.5

Finally the Product has been tested on the panel EFS Ac HCV, lot n° 01/08.03.22C/01/A, supplied by the Etablissement Francais Du Sang (EFS), France, with the following results:

**EFS Panel Ac HCV**

Sample	Lot # 1 S/Co	Lot # 2 S/Co	Lot # 2 S/Co	Results expected
HCV 1	2.2	2.4	2.6	positive
HCV 2	1.6	2.0	2.1	positive
HCV 3	1.5	1.7	1.6	positive
HCV 4	5.2	6.5	5.5	positive
HCV 5	1.6	1.8	1.6	positive
HCV 6	0.4	0.4	0.4	negative

**3. PRECISION:**

It has been calculated on two samples, one negative and one low positive, examined in 16 replicates in three separate runs.

Results are reported as follows:

**Lot # 1202**

**Negative Sample (N = 16)**

Mean values	1st run	2nd run	3 <sup>rd</sup> run	Average value
OD 450nm	0.094	0.099	0.096	0.096
Std.Deviation	0.008	0.007	0.008	0.007
CV %	8.7	6.6	7.9	7.7

**Cal # 2 – 7K (N = 16)**

Mean values	1st run	2nd run	3 <sup>rd</sup> run	Average value
OD 450nm	0.396	0.403	0.418	0.406
Std.Deviation	0.023	0.029	0.027	0.026
CV %	5.9	7.1	6.4	6.5
S/Co	1.1	1.1	1.2	1.1

**Lot # 0602**

**Negative Sample (N = 16)**

Mean values	1st run	2nd run	3 <sup>rd</sup> run	Average
OD 450nm	0.097	0.096	0.094	0.096
Std.Deviation	0.009	0.010	0.008	0.009
CV %	8.9	10.1	8.4	9.1

**Cal # 2 – 7K (N = 16)**

Mean values	1st run	2nd run	3 <sup>rd</sup> run	Average value
OD 450nm	0.400	0.395	0.393	0.396
Std.Deviation	0.021	0.025	0.026	0.024
CV %	5.4	6.2	6.6	6.1
S/Co	1.2	1.2	1.1	1.2

**Lot # 0602/2**

**Negative Sample (N = 16)**

Mean values	1st run	2nd run	3 <sup>rd</sup> run	Average
OD 450nm	0.087	0.091	0.088	0.089
Std.Deviation	0.009	0.007	0.008	0.008
CV %	10.0	8.2	8.6	8.9

**Cal # 2 – 7K (N = 16)**

Mean values	1st run	2nd run	3 <sup>rd</sup> run	Average
OD 450nm	0.386	0.390	0.391	0.389
Std.Deviation	0.023	0.021	0.023	0.022
CV %	6.0	5.3	5.8	5.7
S/Co	1.1	1.2	1.2	1.2

The variability shown in the tables above did not result in sample misclassification.

**S. LIMITATIONS**

Repeatable false positive results, not confirmed by RIBA or similar confirmation techniques, were assessed as less than 0.1% of the normal population.

Frozen samples containing fibrin particles or aggregates after thawing have been observed to generate some false results.

## REFERENCES

1. CDC. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991;40(No. RR-4):1-17.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-5S.
3. McQuillan GM, Alter MJ, Moyer LA, Lambert SB, Margolis HS. A population based serologic study of hepatitis C virus infection in the United States. In Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease, Edizioni Minerva Medica, Turin, 1997, 267-70.
4. Dufour MC. Chronic liver disease and cirrhosis. In Everhart JE, ed. Digestive diseases in the United States: epidemiology and impact. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 1994; NIH publication no. 94-1447, 615-45.
5. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-35.
6. Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972;77:691-9.
7. Alter HJ, Purcell RH, Holland PV, Feinstone SM, Morrow AG, Moritsugu Y. Clinical and serological analysis of transfusion-associated hepatitis. Lancet 1975;2:838-41.
8. Seeff LB, Wright EC, Zimmerman HJ, McCollum RW, VA Cooperative Studies Group. VA cooperative study of post-transfusion hepatitis and responsible risk factors. Am J Med Sci 1975;270:355-62.
9. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-70.
10. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
11. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
12. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
13. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med 1991;325:1325-9.
14. Alter MJ, Margolis HS, Krawczynski K, Judson, FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
15. Alter, MJ. Epidemiology of hepatitis C in the west. Semin Liver Dis 1995;15:5-14.
16. Donahue JG, Nelson KE, Muñoz A, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991;134:1206-11.
17. Zeldis JB, Jain S, Kuramoto IK, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992;156:30-5.
18. Fingerhood MI, Jasinski DR, Sullivan JT. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med 1993;153:2025-30.
19. Garfein RS, Vlahov D, Galai N, Doherty, MC, Nelson, KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Pub Health 1996;86:655-61.
20. Brettler DB, Alter HJ, Deinstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990;76:254-6.
21. Troisi CL, Hollinger FB, Hoots WK, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993;81:412-8.
22. Kumar A, Kulkarni R, Murray DL, et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virology 1993;41:205-9.
23. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO Journal 1998;44:98-107.
24. Osmond DH, Charlebois E, Sheppard HW, et al. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. J Infect Dis 1993;167:66-71.
25. Weinstock HS, Bolan G, Reingold AL, Polish LB: Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases. JAMA 1993;269:392-4.
26. Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994;169:990-5.
27. Buchbinder SP, Katz MH, Hessel NA, Liu J, O'Malley PM, Alter, MJ. Hepatitis C virus infection in sexually active homosexual men. J Infect 1994;29:263-9.
28. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore--an analysis of 309 sex partnerships. J Infect Dis 1995;171:768-75.
29. Thomas DL, Factor SH, Kelen GD, Washington AS, Taylor E Jr, Quinn TC. Viral hepatitis in health care personnel at The Johns Hopkins Hospital. Arch Intern Med 1993;153:1705-12.
30. Cooper BW, Krusell A, Tilton RC, Goodwin R, Levitz RE. Seroprevalence of antibodies to hepatitis C virus in high-risk hospital personnel. Infect Control Hosp Epidemiol 1992;13:82-5.

**This product has been manufactured by Dia. Pro s.r.l. under the controls established by a full quality management system that meets the requirements of ISO 13485 as declared by the EC Notified Body n° 0318**

Produced by  
Dia.Pro. Diagnostic Bioprobes Srl.  
via Columella n°31 – Milano - Italy

Doc.:	INS CVAB.CE	Rev.: 2	01/2007
-------	-------------	---------	---------

